Ionis Pharmaceuticals, Inc. (IONS)
Largest Insider Buys in Sector
IONS Stock Price History Chart
IONS Stock Performance
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered …
Insider Activity of Ionis Pharmaceuticals, Inc.
Over the last 12 months, insiders at Ionis Pharmaceuticals, Inc. have bought $0 and sold $25.77M worth of Ionis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Ionis Pharmaceuticals, Inc. have bought $0 and sold $12.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $12,520 was made by KLEIN JOSEPH III (director) on 2006‑08‑15.
List of Insider Buy and Sell Transactions, Ionis Pharmaceuticals, Inc.
| 2024-11-12 | Sale | Chief Executive Officer | 6,630 0.0042% | $38.05 | $252,294 | -6.27% | ||
| 2024-11-12 | Sale | EVP Research | 1,194 0.0008% | $37.92 | $45,278 | -6.27% | ||
| 2024-11-12 | Sale | director | 13,508 0.0086% | $37.86 | $511,426 | -6.27% | ||
| 2024-10-16 | Sale | EVP Research | 53 <0.0001% | $38.31 | $2,031 | -1.37% | ||
| 2024-08-29 | Sale | EVP, Chief Development Officer | 331 0.0002% | $49.63 | $16,428 | -21.52% | ||
| 2024-08-28 | Sale | EVP, Chief Development Officer | 320 0.0002% | $49.16 | $15,731 | -20.46% | ||
| 2024-08-05 | Sale | EVP, Chief Development Officer | 2,430 0.0017% | $48.00 | $116,640 | -13.40% | ||
| 2024-07-16 | Sale | director | 1,637 0.0012% | $49.49 | $81,019 | -15.35% | ||
| 2024-07-16 | Sale | director | 12,000 0.0086% | $50.00 | $600,000 | -15.35% | ||
| 2024-06-17 | Sale | director | 16,000 0.0111% | $40.29 | $644,640 | +3.72% | ||
| 2024-05-03 | Sale | director | 6,000 0.0042% | $42.71 | $256,277 | -3.74% | ||
| 2024-04-16 | Sale | EVP, Corp and Development Ops | 905 0.0006% | $41.66 | $37,698 | -1.80% | ||
| 2024-04-16 | Sale | EVP, Chief Business Officer | 4,006 0.0028% | $41.60 | $166,641 | -1.80% | ||
| 2024-02-16 | Sale | Chief Executive Officer | 387 0.0003% | $44.49 | $17,219 | -5.42% | ||
| 2024-02-02 | Sale | Chief Executive Officer | 23,907 0.0158% | $49.37 | $1.18M | -14.95% | ||
| 2024-02-02 | Sale | EVP, Finance & CFO | 2,162 0.0014% | $49.54 | $107,105 | -14.95% | ||
| 2024-02-02 | Sale | EVP, Chief Development Officer | 1,995 0.0013% | $50.04 | $99,836 | -14.95% | ||
| 2024-02-02 | Sale | EVP, Chief Scientific Officer | 1,885 0.0013% | $49.52 | $93,337 | -14.95% | ||
| 2024-02-02 | Sale | EVP CLO & General Counsel | 1,995 0.0013% | $49.67 | $99,099 | -14.95% | ||
| 2024-02-02 | Sale | EVP, Chf Clinical Develop Ofcr | 2,106 0.0014% | $49.59 | $104,437 | -14.95% |
Insider Historical Profitability
| KLEIN JOSEPH III | director | 0 0% | $33.84 | 9 | 35 | +49.6% |
Institutional Investor Ownership
| Fidelity Investments | $947.75M | 14.98 | 21.86M | +1.59% | +$14.82M | 0.06 | |
| The Vanguard Group | $582.21M | 9.2 | 13.43M | -5.44% | -$33.51M | 0.01 | |
| T Rowe Price Investment Management Inc | $577.3M | 9.12 | 13.32M | +0.88% | +$5.01M | 0.35 | |
| BlackRock | $423.61M | 6.7 | 9.77M | +7.89% | +$30.97M | 0.01 | |
| Bellevue Group | $359.78M | 5.69 | 8.3M | -4.76% | -$17.97M | 5.52 |